UBS Group AG Registered Ordinary Shares (UBS)

UBS analyst Michael Yee called Novo Nordisk a value trap, but still sees a turnaround playing out over time.

What Happened? Shares of coffeehouse chain Starbucks (NASDAQ:SBUX) fell 2.3% in the afternoon session after Financial Times reported that the company evaluat...

What Happened? Shares of global professional services company Accenture (NYSE:ACN) jumped 4.5% in the afternoon session after the company and Dell Technologi...

Does Chainlink's CCIP 2.0 upgrade matter for LINK holders? It could, but the big banks need to show up first.

The nuclear energy start-up posted a 99% fall in Q2 revenue. Its next earnings report is coming up.

One analyst downgraded the stock to the equivalent of hold.

Morgan Stanley cut its Apple price target to $355 despite raising revenue forecasts, citing softer iPhone pricing and rising memory chip costs squeezing profit margins.

Being first to an approved design hasn't made the reactor developer first to a construction site.

Soaring long-term yields aren't necessarily a bad thing for the S&P 500.

This biotech stock could soar 30% or more over the next 12 months if some analysts are right.

Micron just released another blockbuster set of financial results.

Liberty Energy shares have fallen below $20 after a costly pivot into AI data center power, with analysts split on valuation until a signed power contract materializes.

Space Exploration Technologies wants to become a semiconductor giant.

One firm has a more tempered view of how much room this geothermal stock can run.

Technology stocks have led the market higher in 2026, fueled by the artificial intelligence boom.

U.S. weapons spending could reach $1.5 trillion next year, and two defense contractors are positioned to benefit.

Boeing's 737 MAX 10 may be grounded, but Starliner is ready to fly again.

Lee thinks tailwinds like tokenization and artificial intelligence could spark an incredible rally in the Ether cryptocurrency.

The S&P 500 has seen positive returns in the 12 months after midterm elections 95% of the time since 1938.

There are good reasons behind analyst's bullish views of this biotech stock.

On Sept. 25, 2026, analysts weighed in, with BNP Paribas cutting its price target to $268, keeping investor focus on near-term earnings expectations.

Micron still has plenty of upside potential.

UBS and DA Davidson raised Palantir price targets to $250 on AI sovereignty optimism, while short seller Michael Burry has increased his bet against PLTR, citing valuation and receivables concerns.

UBS analyst Karl Keirstead just put a $250 price target on Palantir stock.

What Happened? Shares of fast-food chain McDonald’s (NYSE:MCD) fell 6.1% in the afternoon session after the company laid out its NEXT strategy in a press rel...